Subtopic Deep Dive
Somatostatin Receptor Imaging
Research Guide
What is Somatostatin Receptor Imaging?
Somatostatin receptor imaging uses radiolabeled somatostatin analogs like [111In-DTPA-d-Phe1]-octreotide and [123I-Tyr3]-octreotide to detect and stage neuroendocrine tumors via scintigraphy and PET-CT.
This modality targets somatostatin receptors overexpressed on neuroendocrine tumors for improved sensitivity and specificity over conventional imaging. Key studies include Krenning et al. (1993) reporting results from over 1000 patients using octreotide-based scintigraphy (1562 citations). Advances extend to therapy selection for peptide receptor radionuclide therapy (Kwekkeboom et al., 2008, 1422 citations).
Why It Matters
Somatostatin receptor imaging enables precise detection and staging of neuroendocrine tumors, guiding targeted therapies like 177Lu-DOTATATE, which prolonged progression-free survival in midgut NETs (Strosberg et al., 2017, 2973 citations). It supports patient selection for somatostatin analogs such as lanreotide, improving outcomes in metastatic enteropancreatic NETs (Caplin et al., 2014, 1875 citations). Clinical utility includes identifying candidates for radiolabeled therapies, reducing futile treatments (Kwekkeboom et al., 2008).
Key Research Challenges
Variability in Receptor Expression
Heterogeneous somatostatin receptor density across NET subtypes limits imaging sensitivity. Krenning et al. (1993) noted variable uptake in over 1000 patients. Patel (1999) detailed five receptor subtypes influencing tracer binding.
Comparison of Radioligands
Differences in affinity and pharmacokinetics between [111In]-octreotide, DOTATOC, and newer agents complicate modality selection. Kwekkeboom et al. (2008) compared efficacy for therapy planning. Reubi (2003) analyzed peptide receptor targeting principles (1119 citations).
Integration with Staging Systems
Aligning imaging findings with TNM and WHO grading remains inconsistent for foregut NETs. Rindi et al. (2006) proposed consensus TNM staging with grading (1567 citations). Rindi et al. (2018) updated classification framework (1077 citations).
Essential Papers
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari, Chan Shen, Daniel M. Halperin et al. · 2017 · JAMA Oncology · 3.4K citations
The incidence and prevalence of NETs are steadily rising, possibly owing to detection of early-stage disease and stage migration. Survival for all NETs has improved over time, especially for distan...
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · 2017 · New England Journal of Medicine · 3.0K citations
Treatment with <sup>177</sup>Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced mi...
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła et al. · 2014 · New England Journal of Medicine · 1.9K citations
Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%). (Funded by Ipsen...
Somatostatin and Its Receptor Family
Yogesh Patel · 1999 · Frontiers in Neuroendocrinology · 1.6K citations
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Guido Rindi, G. Klöppel, H. Alhman et al. · 2006 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 1.6K citations
Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
E. P. Krenning, Dik J. Kwekkeboom, Willem H. Bakker et al. · 1993 · European Journal of Nuclear Medicine and Molecular Imaging · 1.6K citations
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · 2008 · Journal of Clinical Oncology · 1.4K citations
Purpose Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metast...
Reading Guide
Foundational Papers
Start with Krenning et al. (1993) for clinical scintigraphy experience in 1000+ patients, Patel (1999) for receptor biology, and Kwekkeboom et al. (2008) for PRRT efficacy linking imaging to therapy.
Recent Advances
Study Strosberg et al. (2017) for 177Lu-DOTATATE trial outcomes and Rindi et al. (2018) for updated NET classification integrating imaging data.
Core Methods
Core techniques: octreotide scintigraphy (Krenning et al., 1993), peptide receptor targeting (Reubi, 2003), and PET-CT for staging (Falconi et al., 2016 guidelines).
How PapersFlow Helps You Research Somatostatin Receptor Imaging
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map somatostatin receptor imaging literature, starting from Krenning et al. (1993, 1562 citations) to find descendants like Strosberg et al. (2017). exaSearch uncovers recent DOTATOC/PET-CT comparisons, while findSimilarPapers expands from Kwekkeboom et al. (2008) on 177Lu-DOTATATE selection.
Analyze & Verify
Analysis Agent employs readPaperContent on Krenning et al. (1993) to extract sensitivity data from 1000+ patients, then verifyResponse with CoVe checks claims against Reubi (2003). runPythonAnalysis performs statistical verification of survival metrics from Strosberg et al. (2017) using pandas for PFS comparisons, with GRADE grading for evidence quality in therapy selection.
Synthesize & Write
Synthesis Agent detects gaps in receptor subtype imaging via contradiction flagging across Patel (1999) and Kwekkeboom et al. (2008). Writing Agent uses latexEditText and latexSyncCitations to draft NET staging reviews, latexCompile for publication-ready PDFs, and exportMermaid for visualizing SSTR imaging workflows.
Use Cases
"Compare sensitivity of [111In]-octreotide vs DOTATOC PET in pancreatic NETs"
Research Agent → searchPapers + findSimilarPapers → Analysis Agent → readPaperContent (Krenning 1993) + runPythonAnalysis (meta-analysis of sensitivity stats) → GRADE-graded comparison table.
"Draft LaTeX review on SSTR imaging for PRRT patient selection"
Synthesis Agent → gap detection (Kwekkeboom 2008, Strosberg 2017) → Writing Agent → latexEditText + latexSyncCitations + latexCompile → camera-ready LaTeX manuscript with diagrams.
"Find code for SSTR PET quantification analysis"
Research Agent → paperExtractUrls + paperFindGithubRepo → Code Discovery → githubRepoInspect → runnable Python scripts for SUV analysis from DOTATOC studies.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ SSTR imaging papers: citationGraph from Krenning (1993) → DeepScan 7-step analysis with CoVe checkpoints on sensitivity claims → structured report with GRADE scores. Theorizer generates hypotheses on multimodal imaging by synthesizing Patel (1999) receptor biology with Strosberg (2017) trial data. DeepScan verifies staging integration via Rindi (2006) consensus against recent WHO updates.
Frequently Asked Questions
What is somatostatin receptor imaging?
It employs radiolabeled analogs like [111In-DTPA-d-Phe1]-octreotide to visualize somatostatin receptors on NETs via scintigraphy (Krenning et al., 1993).
What are key methods in SSTR imaging?
Primary methods include [111In]- and [123I]-octreotide scintigraphy (Krenning et al., 1993) and DOTATOC/PET-CT for higher resolution, used in PRRT selection (Kwekkeboom et al., 2008).
What are key papers on SSTR imaging?
Foundational: Krenning et al. (1993, 1562 citations, 1000+ patients); Kwekkeboom et al. (2008, 1422 citations, PRRT outcomes). Recent: Strosberg et al. (2017, 2973 citations, 177Lu-DOTATATE trial).
What are open problems in SSTR imaging?
Challenges include receptor heterogeneity (Patel, 1999), radioligand comparisons (Reubi, 2003), and staging alignment (Rindi et al., 2006; 2018).
Research Neuroendocrine Tumor Research Advances with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Somatostatin Receptor Imaging with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers